参麦注射液对急性心肌梗死病死率影响的系统评价及试验序贯分析  

Systematic Evaluation and Trial Sequential Analysis of Shenmai Injection on Mortality Rate of Patients with Acute Myocardial Infarction

作　　者：王震[1,2] 鞠建庆[1] 李运伦[1,2] 

机构地区：[1]山东中医药大学第一临床医学院,济南250355 [2]山东中医药大学附属医院,济南250011

出　　处：《中国实验方剂学杂志》2015年第19期189-193,共5页Chinese Journal of Experimental Traditional Medical Formulae

基　　金：国家自然科学基金项目(81273700)

摘　　要：目的:系统评价参麦注射液对急性心肌梗死病死率的影响。方法:检索电子数据库,搜集以病死率为结局评价参麦注射液治疗急性心肌梗死(AMI)的随机对照试验,进行系统评价和Meta分析,并按照发表年份进行累积Meta分析,然后采用序贯试验分析(TSA)的方法对结果进行检验。结果:共纳入16项合格研究,Meta分析和累积Meta分析结果显示参麦注射液可降低AMI的病死率,[RR=0.61,99%CI(0.43,0.85)],[RD=-0.06,99%CI(-0.09,-0.03),NNT≈15.3],TSA分析进一步确证了该结果。结论:参麦注射液可降低AMI患者的病死率,但由于研究的局限性,仍建议今后开展设计合理、执行严格的临床试验以提供更加真实可靠的证据。Objective： To systematically assess the efficacy of Shenmai injection on the mortality rate of patients with acute myocardial infarction （AMI）. Method： Randomized controlled trials for evaluating Shenmai injection for AMI patients with the mortality rate as an outcome were collected from electronic databases for a systematic evaluation and meta-analysis. Besides, a cumulative meta-analysis according to the year of publication was conducted, and trial sequential analysis （TSA） was also adopted to test their results. Result： Sixteen qualified trials were included. Meta-analysis and cumulative meta-analysis indicated that Shenmai injection can decrease the mortality rate of AMI patients, with RR =0.61, 99%CI （0.43, 0.85）, RD = -0.06, 99%CI （ - 0.09, - 0.03）, NNT≈15.3. TSA further verified the results. Conclusion： Shenmai injection can decrease the mortality rate of patients with AMI. Due to the limitations of the study, clinical trials with rational design and strict execution shall be carried out in the future to provide more reliable evidence.

关 键 词：参麦注射液 急性心肌梗死 系统评价 META分析 试验序贯分析 

分 类 号：R287.6[医药卫生—中药学]